HC Wainwright Predicts Immunic's Q3 Earnings (NASDAQ:IMUX)

Key Points

• HC Wainwright raised Immunic’s Q3 2026 EPS forecast to a loss of $0.74 per share from $2.21 and maintained a Buy rating with a $22 price target.
• The firm projects Immunic’s losses will narrow steadily through 2029, with the company reaching positive EPS of $0.40 in 2030.
• Immunic recently reported a quarterly loss of $0.80 per share, beating the consensus estimate of a $1.16 loss; analysts overall hold a consensus Buy rating, although the company remains unprofitable and its outlook depends on successful pipeline development.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Immunic in a research note issued on Thursday, August 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.74) for the quarter, up from their prior forecast of ($2.21). HC Wainwright currently has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Immunic's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Immunic's Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.18) EPS, FY2027 earnings at ($2.47) EPS, FY2028 earnings at ($1.45) EPS, FY2029 earnings at ($0.53) EPS and FY2030 earnings at $0.40 EPS.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36.

A number of other research firms have also recently weighed in on IMUX. Roth Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Immunic in a report on Thursday, May 14th. B. Riley Financial lowered their target price on Immunic from $40.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 22nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunic in a research note on Friday, May 29th. LADENBURG THALM/SH SH upgraded Immunic to a "strong-buy" rating in a research report on Wednesday, July 29th. Finally, Lifesci Capital raised Immunic to a "strong-buy" rating in a research note on Monday, May 4th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $47.57.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $16.06 on Monday. The firm's 50 day moving average is $14.45 and its two-hundred day moving average is $12.10. Immunic has a 52 week low of $5.06 and a 52 week high of $16.86. The firm has a market capitalization of $219.06 million, a P/E ratio of -3.67 and a beta of 1.41.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC lifted its position in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares during the period. Vanguard Group Inc. raised its stake in shares of Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company's stock worth $3,832,000 after buying an additional 219,957 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Immunic in the 3rd quarter worth $239,000. Two Sigma Investments LP acquired a new stake in shares of Immunic in the third quarter valued at $52,000. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at $99,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic News Roundup

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright significantly improved its earnings forecasts across 2026–2030. The firm now projects smaller losses of $3.18 per share in 2026, $2.47 in 2027, $1.45 in 2028 and $0.53 in 2029, followed by positive EPS of $0.40 in 2030. HC Wainwright maintained a Buy rating and a $22 price target, suggesting potential upside from current levels.
• Positive Sentiment: HC Wainwright also raised its third- and fourth-quarter 2026 EPS estimates to losses of $0.74 and $0.68, respectively, from substantially larger projected losses. This indicates expectations for improved operating performance and a faster path toward profitability.
• Positive Sentiment: Brookline Capital Markets raised its full-year 2026 EPS forecast to a $3.86 loss from a $4.34 loss and improved its third-quarter estimate to a $0.84 loss from $1.07, reinforcing the view that Immunic’s near-term losses could narrow.
• Neutral Sentiment: Wall Street Zen upgraded its assessment of Immunic to Hold. The rating is less bullish than HC Wainwright’s view and could limit enthusiasm among investors seeking a stronger consensus signal. Immunic Raised to Hold at Wall Street Zen
• Negative Sentiment: Brookline slightly reduced its fourth-quarter 2026 estimate to a $1.16-per-share loss from $1.14. More broadly, Immunic remains unprofitable, with the analyst consensus calling for a $4.49-per-share loss in the current year. The company’s valuation therefore remains highly dependent on successful development and eventual commercialization of its pipeline.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source